Back to Journals » Cancer Management and Research » Volume 11

RETRACTED ARTICLE: MicroRNA-506 regulates apoptosis in retinoblastoma cells by targeting sirtuin 1

Authors Song Z, Wang H, Zong F, Zhu C, Tao Y

Received 5 April 2019

Accepted for publication 19 August 2019

Published 16 September 2019 Volume 2019:11 Pages 8419—8429

DOI https://doi.org/10.2147/CMAR.S211122

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Beicheng Sun



This paper has been retracted.

Song Z, Wang H, Zong F, Zhu C, Tao Y. Cancer Manag Res. 2019;11:8419–8429.

We, the Editors and Publisher of Cancer Management and Research, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figures 4 and 6 with images from other unrelated articles. Specifically,

  • Images for Figures 4A and 4B have been duplicated with images for Figures 4A and 4B from Zhong R, et al (2019); Figure 4A from Cai C, et al (2019); Figures 4A and 4B from Li M, Meng X, Li M. MiR-126 promotes esophageal squamous cell carcinoma via inhibition of apoptosis and autophagy. Aging (Albany NY). 2020;12:12107-12118. https://doi.org/10.18632/aging.103379 and Figure 4A from Si H, Zhang Y, Song Y, Li L. Overexpression of adrenomedullin protects mesenchymal stem cells against hypoxia and serum deprivation‑induced apoptosis via the Akt/GSK3β and Bcl‑2 signaling pathways. International Journal of Molecular Medicine. 2018;41:3342-3352. https://doi.org/10.3892/ijmm.2018.3533.
  • Images for Figure 4C and 4D have been duplicated with images for Figure 4B from Cai C, Min S, Yan B, et al. MiR-27a promotes the autophagy and apoptosis of IL-1β treated-articular chondrocytes in osteoarthritis through PI3K/AKT/mTOR signaling. Aging (Albany NY). 2019;11:6371-6384. https://doi.org/10.18632/aging.102194 (RETRACTED) and Figures 4c and 4d from Zhong R, Li S, Fang K, Yang L, Wang L. microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting JAK1. Cell Cycle. 2019;18(9):990-1000. https://doi.org/10.1080/15384101.2019.1608127.
  • Images for Figures 6A and 6B have been duplicated with images for Figure 3C from Zhou J, Zhang Y, Han Z, et al. RETRACTED ARTICLE: miR-506 contributes to malignancy of cutaneous squamous cell carcinoma via targeting of P65 and LAMC1. Cell Cycle. 2019;18(3):333-345. https://doi.org/10.1080/15384101.2019.1568747; Figure 4C from Ouyang L, Yi L, Li J, et al. SIRT6 overexpression induces apoptosis of nasopharyngeal carcinoma by inhibiting NF-κB signaling. Onco Targets Ther. 2018;11:7613-7624. https://doi.org/10.2147/OTT.S179866; Figures 6a and 6b from Zhong R, Li S, Fang K, Yang L, Wang L. (2019) microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting JAK1. Cell Cycle. 2019;18(9):990-1000. https://doi.org/10.1080/15384101.2019.1608127, and Figure 8A from Huang L, Jian Z, Gao Y, et al. RPN2 promotes metastasis of hepatocellular carcinoma cell and inhibits autophagy via STAT3 and NF-κB pathways. Aging (Albany NY). 2019;11:6674-6690. https://doi.org/10.18632/aging.102167.

The authors did not respond to our queries and were unable to provide an explanation for the duplicated images or provide data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.